The British Association of Dermatologists’ Biologic Interventions Register (BADBIR) was set up by the BAD* to follow up all patients receiving biologic therapy for psoriasis in the UK and Eire.
Its aim is to investigate the long-term safety for patients treated with biologic agents, compared with conventional systemic therapy.
BAD guidelines strongly recommend that all psoriasis patients on biologic therapies should be registered with BADBIR, which also has strong support from NICE.†
ALERT: BAD position statement on biosimilars 2017
Please contact Dr Sagair Hussain for your login and password for the online GCP training course.
The BAD Biologics Team:
Dr Sagair Hussain
BAD Biologics Manager
Tel: 020 7391 6083
*Financially supported by AbbVie, Janssen-Cilag, Novartis, Samsung Bioepis, Eli Lilly, Hexal AG, Celgene, Almirall, Leo Pharma, UCB and Amgen. †NICE TA103 and TA180.
The British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Chair of the Data Monitoring Committee